Xanomeline is a muscarinic agonist used in conjunction with trospium, a muscarinic antagonist, to treat schizophrenia. Schizophrenia is a complex disease involving a number of different neurotransmitters, including serotonin, dopamine, and acetylcholine.
- Mechanism
- Curator reviewed · 2 references
The efficacy of xanomeline in the treatment of schizophrenia is thought to be due to its agonist activity at muscarinic acetylcholine receptors M1 and M4 in the central nervous system. It binds to muscarinic receptors M1 to M5 with comparable affinity and exhibits relatively higher agonist activity at the M1 and M4 receptors.
- Primary indication
- Xanomeline is indicated in combination with trospium for the treatment of schizophrenia in adults.Curator reviewed · 1 structured indication
- Formula / weight
- C14H23N3OS · 281.42 g/mol (avg)
- First approval
- United States, 2024
- Code names
- LY-246708
- Brand names
Resolves to
JOLJIIDDOBNFHW-UHFFFAOYSA-NSMILESCCCCCCOC1=NSN=C1C1=CCCN(C)C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Xanomeline, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account